Synthetic microparticles conjugated with VEGF165 improve the survival of endothelial progenitor cells via microRNA-17 inhibition

Several cell-based therapies are under pre-clinical and clinical evaluation for the treatment of ischemic diseases. Poor survival and vascular engraftment rates of transplanted cells force them to work mainly via time-limited paracrine actions. Although several approaches, including the use of solub...

ver descrição completa

Detalhes bibliográficos
Autor principal: Aday, Sezin (author)
Outros Autores: Zoldan, Janet (author), Besnier, Marie (author), Carreto, Laura (author), Saif, Jaimy (author), Fernandes, Rui (author), Santos, Tiago (author), Bernardino, Liliana Inácio (author), Langer, Robert (author), Emanueli, Costanza (author), Ferreira, Lino (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
Cell- and Tissue-Based Therapy
Cell-Derived Microparticles
Cyclin-Dependent Kinase Inhibitor p21
DNA-Binding Proteins
Endothelial Progenitor Cells
Fetal Blood
Gene Expression Regulation
Human Umbilical Vein Endothelial Cells
Humans
Ischemia
MicroRNAs
Neovascularization, Physiologic
Phosphorylation
Proto-Oncogene Proteins c-akt
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
Cell Survival
Texto completo:http://hdl.handle.net/10316/92390
País:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/92390

Texto Completo

http://hdl.handle.net/10316/92390

Registos relacionados